These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 16731546

  • 1. Duration not severity of the climacteric syndrome predicts resumption of hormone therapy after discontinuation: a prospective cohort study.
    Haimov-Kochman R, Barak-Glantz E, Ein-Mor E, Arbel R, Brzezinski A, Milwidsky A, Hochner-Celnikier D.
    Hum Reprod; 2006 Sep; 21(9):2450-4. PubMed ID: 16731546
    [Abstract] [Full Text] [Related]

  • 2. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study.
    Haimov-Kochman R, Barak-Glantz E, Arbel R, Leefsma M, Brzezinski A, Milwidsky A, Hochner-Celnikier D.
    Menopause; 2006 Sep; 13(3):370-6. PubMed ID: 16735933
    [Abstract] [Full Text] [Related]

  • 3. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.
    Du Y, Scheidt-Nave C, Schaffrath Rosario A, Ellert U, Dören M, Knopf H.
    Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms.
    Lindh-Astrand L, Bixo M, Hirschberg AL, Sundström-Poromaa I, Hammar M.
    Menopause; 2010 Aug; 17(1):72-9. PubMed ID: 19675505
    [Abstract] [Full Text] [Related]

  • 5. Measuring climacteric symptoms in an Ecuadorian population with the Greene Climacteric Scale.
    Sierra B, Hidalgo LA, Chedraui PA.
    Maturitas; 2005 Jul 16; 51(3):236-45. PubMed ID: 15978967
    [Abstract] [Full Text] [Related]

  • 6. Greene Climacteric Scale: norms in an Australian population in relation to age and menopausal status.
    Travers C, O'Neill SM, King R, Battistutta D, Khoo SK.
    Climacteric; 2005 Mar 16; 8(1):56-62. PubMed ID: 15804732
    [Abstract] [Full Text] [Related]

  • 7. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast.
    Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC.
    Taiwan J Obstet Gynecol; 2007 Jun 16; 46(2):127-34. PubMed ID: 17638620
    [Abstract] [Full Text] [Related]

  • 8. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?
    Haskell SG, Bean-Mayberry B, Gordon K.
    Menopause; 2009 Jun 16; 16(3):494-9. PubMed ID: 19182695
    [Abstract] [Full Text] [Related]

  • 9. Duration of vasomotor symptoms in middle-aged women: a longitudinal study.
    Col NF, Guthrie JR, Politi M, Dennerstein L.
    Menopause; 2009 Jun 16; 16(3):453-7. PubMed ID: 19188852
    [Abstract] [Full Text] [Related]

  • 10. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study.
    Lindh-Astrand L, Brynhildsen J, Hoffman M, Hammar M.
    Menopause; 2009 Jun 16; 16(6):1213-7. PubMed ID: 19455070
    [Abstract] [Full Text] [Related]

  • 11. Hormone therapy use among postmenopausal French women before the publication of the Women's Health Initiative study: duration of use and factors associated with discontinuation.
    Ringa V, Varnoux N, Piault S, Bréart G.
    Fertil Steril; 2005 Jun 16; 83(6):1771-9. PubMed ID: 15950650
    [Abstract] [Full Text] [Related]

  • 12. Treatment of climacteric symptoms in Finland prior to the controversial reports on hormone therapy.
    Jalava-Broman J, Mäkinen J, Ojanlatva A, Jokinen K, Sillanmäki L, Rautava P.
    Acta Obstet Gynecol Scand; 2008 Jun 16; 87(6):682-6. PubMed ID: 18568469
    [Abstract] [Full Text] [Related]

  • 13. Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale.
    Kapur P, Sinha B, Pereira BM.
    Menopause; 2009 Jun 16; 16(2):378-84. PubMed ID: 19057415
    [Abstract] [Full Text] [Related]

  • 14. Risk of onset of menopausal symptoms in periods surrounding menopause.
    Sabia S, Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F.
    Maturitas; 2007 Dec 20; 58(4):340-7. PubMed ID: 17981410
    [Abstract] [Full Text] [Related]

  • 15. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA.
    Breast Cancer Res Treat; 2009 Aug 20; 116(3):521-7. PubMed ID: 19139988
    [Abstract] [Full Text] [Related]

  • 16. Women's views of the climacteric at the time of low menopausal hormone use, Estonia 1998.
    Hovi SL, Veerus P, Karro H, Topo P, Hemminki E.
    Maturitas; 2005 Aug 16; 51(4):413-25. PubMed ID: 16039416
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Factors associated with treatment options among menopausal women in Taiwan.
    Chiou YW, Tai CJ, Chien LY.
    Maturitas; 2006 Jun 20; 54(3):205-12. PubMed ID: 16303267
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.